المؤلفون: A. E. Kalinin, I. G. Avdyukhin, S. N. Nered, N. S. Besova, A. A. Tryakin, E. V. Artamonova, T. A. Titova, E. S. Obarevich, E. O. Ignatova, N. A. Kozlov, O. V. Rossomakhina, N. A. Shishkina, E. S. Kolobanova, O. A. Malikhova, M. G. Abgaryan, M. P. Nikulin, P. P. Arkhiri, L. A. Vashakmadze, I. N. Peregorodiev, E. A. Suleimanov, I. S. Stilidi, А. Е. Калинин, И. Г. Авдюхин, С. Н. Неред, Н. С. Бесова, А. А. Трякин, Е. В. Артамонова, Т. А. Титова, Е. С. Обаревич, Е. О. Игнатова, Н. А. Козлов, О. В. Россомахина, Н. А. Шишкина, Е. С. Колобанова, О. А. Малихова, М. Г. Абгарян, М. П. Никулин, П. П. Архири, Л. А. Вашакмадзе, И. Н. Перегородиев, Э. А. Сулейманов, И. С. Стилиди

المصدر: Malignant tumours; Том 13, № 4 (2023); 7-17 ; Злокачественные опухоли; Том 13, № 4 (2023); 7-17 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: FOLFIRINOX, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, FLOT, аденокарцинома желудка, аденокарцинома кардиоэзофагеального перехода

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1273/911; Al-Batran SE, Homann N, Pauligk C. et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4) : a randomised, phase 2 / 3 trial. Lancet. 2019 May 11; 393 (10179) : 1948–1957. doi:10.1016/S0140-6736(18)32557-1. Epub 2019 Apr 11. PMID: 30982686.; Al-Batran SE, Hofheinz RD, Pauligk C et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO) : results from the phase 2 part of a multicentre, open-label, randomised phase 2 / 3 trial. Lancet Oncol. 2016 Dec; 17 (12) : 1697–1708. doi:10.1016/S1470-2045(16)30531-9. Epub 2016 Oct 22. PMID: 27776843.; Stark AP, Ikoma N, Chiang YJ et al. Characteristics and Survival of Gastric Cancer Patients with Pathologic Complete Response to Preoperative Therapy. Ann Surg Oncol. 2019 Oct; 26 (11) : 3602–3610. doi:10.1245/s10434-019-07638-8. Epub 2019 Jul 26. PMID: 31350645.; Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994; 73 : 2680–6.; Lauren P. The two histological main types of gastric carcinoma : diff use and so-called intestinal-type carcinoma. An attempt at a histo-clinical classifi cation. Acta Pathol Microbiol Scand 1965; 64 : 31–49.; Dindo D, Demartines N, Clavien PA. Classification of surgical complications : a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240 (2) : 205–213.; Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M. et al. Cancer incidence and mortality worldwide : sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136 : E359–86).; Cunningham D, Allum WH, Stenning SP, Thompson JN, et al.Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355 : 11–20.; Ychou,M, Boige, V, Pignon,J-P, Conroy T,et al. Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma : An FNCLCC and FFCD Multicenter Phase III Trial. J Clin Oncol 29 : 1715–1721).; Трусилова, Е. Эффективность и токсичность химиотерапии по схеме FOLFIRINOX у больных диссеминированным раком желудка. Предварительные результаты / Е.В. Трусилова, Н.С. Бесова, В.А. Горбунова и др. // Эффективная фармакотерапия. Онкология, гематология, радиология .– 2013 .– Т. 46 (4) .– С. 6–13.; International Union Against Cancer (UICC). TNM Classification of Malignant Tumours, 7th ed. Sobin L.H., Gospodarowicz M.K., Wittekind Ch., eds. New York : Wiley-Blackwell; 2009.; https://www.malignanttumors.org/jour/article/view/1273

الاتاحة: https://www.malignanttumors.org/jour/article/view/1273
https://doi.org/10.18027/2224-5057-2023-13-4-7-17

المؤلفون: I. G. Avdyukhin, I. N. Peregorodiev, А. Е. Kalinin, S. N. Nered, N. S. Besova, А. А. Tryakin, Е. V. Artamonova, Т. А. Titova, Е. S. Obarevich, Е. О. Ignatova, N. А. Kozlov, О. V. Rossomakhina, N. А. Shishkina, Е. S. Kolobanova, О. А. Malikhova, М. G. Abgaryan, М. P. Nikulin, P. P. Arkhiri, L. А. Vashakmadze, S. Hengyan, E. А. Suleimanov, I. S. Stilidi, И. Г. Авдюхин, И. Н. Перегородиев, А. Е. Калинин, С. Н. Неред, Н. С. Бесова, А. А. Трякин, Е. В. Артамонова, Т. А. Титова, Е. С. Обаревич, Е. О. Игнатова, Н. А. Козлов, О. В. Россомахина, Н. А. Шишкина, Е. С. Колобанова, О. А. Малихова, М. Г. Абгарян, М. П. Никулин, П. П. Архири, Л. А. Вашакмадзе, Хэнянь Сунь, Э. А. Сулейманов, И. С. Стилиди

المصدر: Malignant tumours; Том 12, № 4 (2022); 5-13 ; Злокачественные опухоли; Том 12, № 4 (2022); 5-13 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: режим FLOT, gastroesophageal junction adenocarcinoma, perioperative chemotherapy, FLOT regimen, аденокарцинома кардиоэзофагеального перехода, периоперационная химиотерапия

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1016/713; Reim D, Loos M, Vogl F, et al. Prognostic implications of the seventh edition of the International Union Against Cancer classification for patients with gastric cancer: the Western experience of patients treated in a single-center European institution. J Clin Oncol 2013; 31 : 263–71.; Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355 : 11–20.; Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011; 29 : 1715–21.; van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366 : 2074–84.; Ronellenfitsch U, Schwarzbach M, Hofheinz R, et al. Preoperative chemo (radio) therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data. Eur J Cancer 2013; 49 : 3149–58.; Schuhmacher C, Gretschel S, Lordick F, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol 2010; 28 : 5210–18.; Stark AP, Ikoma N, Chiang YJ et al. Characteristics and Survival of Gastric Cancer Patients with Pathologic Complete Response to Preoperative Therapy. Ann Surg Oncol. 2019 Oct; 26 (11) : 3602–3610. doi : 10.1245/s10434-019-07638-8. Epub 2019 Jul 26. PMID : 31350645.; Becker K, Langer R, Reim D, et al. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg 2011; 253 : 934–39.; Alderson D, Langley RE, Nankivell MG, et al. Neoadjuvant chemotherapy for resectable oesophageal and junctional adenocarcinoma: results from the UK Medical Research Council randomised OEO5 trial (ISRCTN 01852072). Proc Am Soc Clin Oncol 2015; 33 (suppl) : 4002 (abstr).; Cunningham D, Smyth E, Stenning S, et al. Peri-operative chemotherapy±bevacizumab for resectable gastro-oesophageal adenocarcinoma: results from the UK Medical Research Council randomised ST03 trial (ISRCTN 46020948). Eur J Cancer 2015; 51 (suppl 3) : S400.; Donohoe CL, O'Farrell NJ, Grant T, et al. Classification of pathologic response to neoadjuvant therapy in esophageal and junctional cancer: assessment of existing measures and proposal of a novel 3-point standard. Ann Surg 2013; 258 : 784–92.; https://www.malignanttumors.org/jour/article/view/1016

الاتاحة: https://www.malignanttumors.org/jour/article/view/1016
https://doi.org/10.18027/2224-5057-2022-12-4-5-13